For US Healthcare Professionals
Prescribing Information
POSLUMA logo

REVEAL WHAT’S REAL: LOW URINARY BLADDER ACTIVITY

Low Urinary levels icon

Low urinary bladder activity in POSLUMA PET scans

Urinary bladder activity in patients with prostate cancer who are undergoing PET scans can interfere with the clear assessment of images. Often, urinary bladder activity appears indistinguishable from disease. This is especially true in the prostate/prostate bed, and pelvic lymph node regions.1

In a majority of patients, POSLUMA has demonstrated either no urinary bladder activity or activity readily distinguishable from disease.1

SEE FOR YOURSELF

REVEAL WHAT’S REAL

Your imaging experience

1/4

Dialogue box icon

Question 1

How often do your PET scans show urinary bladder activity that makes it difficult to distinguish disease?

Question mark icon

DID YOU KNOW?

With POSLUMA, 96% of patients exhibited either no urinary activity in the bladder or activity that was readily distinguishable from disease.1

2/4

Dialogue box icon

Question 2

What proactive steps do you take to mitigate the risk of urinary bladder activity obscuring areas of interest vital to your interpretation? (Select all that apply.)

Question mark icon

DID YOU KNOW?

POSLUMA does not require coadministration with a diuretic, fasting, or administration of IV fluids—yet still demonstrated low urinary bladder activity that does not impact image interpretation in a majority of patients.1,2

3/4

Dialogue box icon

Question 3

If you are able to distinguish disease in the patient case study below, in what region(s) would you identify it? (Select all that apply.)

Patient 1 Case Study: Clinical History

Diagnosed with unfavorable intermediate-risk prostate cancer at age 61

  • Gleason score: 4+3
  • PSA level at scan time: 14.70 ng/mL
  • TNM stage at study entry: cT1 N0 M0

Received a POSLUMA PET scan as part of the LIGHTHOUSE study in March 2021.

4/4

Dialogue box icon

Question 4

If you are able to distinguish disease in the patient case study below, in what region(s) would you identify it? (Select all that apply.)

Patient 2 Case Study: Clinical History

Diagnosed with prostate cancer in October 2019 at age 72

  • Gleason score: 4+5
  • TNM stage: T3a N1 Mx

Initial treatment of radical prostatectomy in January 2020

Elevated PSA levels post-treatment (doubling time not available)

  • 0 ng/mL (February 2020)
  • 0.23 ng/mL (August 2020)
  • 1.51 ng/mL (October 2020)

Received a POSLUMA PET scan as part of the SPOTLIGHT study in November 2020 at age 73.

See how POSLUMA demonstrated low urinary bladder activity that did not impact image interpretation in a majority of patients.1

IN A POST HOC ANALYSIS

POSLUMA demonstrated low urinary bladder interference

This post hoc analysis of 2 pivotal Phase 3 studies was conducted to assess urinary bladder activity associated with POSLUMA and its impact on image interpretation. 712 PET scans were evaluable, 348 from LIGHTHOUSE and 364 from SPOTLIGHT, by 3 board-certified nuclear medicine physicians: quantitatively by 1 and qualitatively by all 3.1,2

MAJORITY READ

96% exhibited no urinary activity or activity readily distinguishable from disease

of patients (682/712) exhibited either no urinary activity in the bladder or activity that was readily distinguishable from disease.1

Qualitative scoring of urinary bladder activity (majority read)1*

  • 11% (77/712) scored 0
  • 85% (605/712) scored 1
  • 3.4% (24/712) scored 2
  • 1% (6/712) scores were tied

*Using SUV data from Reader 1’s analysis, the median SUVmax for urinary bladder activity scores of 0, 1, 2, or tied were 5.2, 18.8, 25.6, and 7.0, respectively.

How might the information you just learned about POSLUMA impact your decision about which imaging agent to use?

Consider how many of your patients might benefit from enhanced visualization with low bladder activity with POSLUMA.1

Thank you

Ready to learn more about POSLUMA?

Learn more about dosing and administration with POSLUMA

Dosing

See how low urinary bladder activity improves tumor-to-background ratio

Efficacy
Image interpretation training icon

Access image interpretation training with POSLUMA

Choose another revealing POSLUMA experience.

Low PSA levels

References: 1. Kuo PH, Hermsen R, Penny R, Postema EJ. Quantitative and qualitative assessment of urinary activity of 18F-flotufolastat-PET/CT in patients with prostate cancer: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies. Mol Imaging Biol. 2024;26(1):53-60. doi:10.1007/s11307-023-01867-w 2. POSLUMA. Package insert. Blue Earth Diagnostics, Ltd; 2023.